Engineered immune cells take aim at tough blood cancers
NCT ID NCT02935257
Summary
This early-stage trial is testing a personalized cell therapy for adults with certain advanced or relapsed blood cancers that have not responded to standard treatments. Doctors collect a patient's own immune cells, genetically modify them in a lab to better target cancer cells, and then infuse them back into the patient. The main goals are to see if this process is safe and feasible, and to check for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOBLASTIC, ACUTE, LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College London Hospital
London, United Kingdom
Conditions
Explore the condition pages connected to this study.